The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...

This discussion emphasizes practical implementation. Freedland outlines how urologists and medical oncologists can collaborate to ensure timely therapy initiation and shares insights into patient- and ...

The ExactVu micro-ultrasound platform is noninferior to MRI in detecting clinically significant prostate cancer in biopsy-naïve men. Microultrasonography offers a cost-effective, in-office alternative ...

Treatment intensification with ARPIs and chemotherapy has transformed mCSPC management, expanding the urologist's role in early treatment phases. Darolutamide is highlighted for its favorable safety ...

In an interview at the 2025 LUGPA Annual Meeting, Stacy Loeb, MD, shared key takeaways from her session, “Current state of prostate cancer screening.” Loeb is a urologists at NYU Langone Health in New ...

Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...

The PR.21 study found no significant difference in rPFS between 177Lu-PSMA-617 and docetaxel in mCRPC patients. 177Lu-PSMA-617 showed a higher PSA response rate compared to docetaxel, with 36% vs 16% ...

Chandler Park, MD, MSc, FACP, interviews urologist Neal D. Shore, MD, FACS, on the top updates in prostate cancer and bladder cancer at the 2025 European Society for Medical Oncology Congress. At the ...

MRWS demonstrated efficacy and safety in oligometastatic ccRCC, with a median PFS of 18 months and STFS of 34 months. Overall survival rates were high, with 94% at 2 years and 86% at 3 years, ...

Prostate cancer awareness is crucial year-round, emphasizing screening and meaningful conversations about risk and prevention. Screening guidelines vary, focusing on shared decision-making and ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” says Dean Elterman, MD. “We're now entering an era of new types of technologies to treat BPH in a ...